Sedona Waterproofing Solutions Provides Expert Crawl Space Encapsulation Services

Sedona Waterproofing Solutions Provides Expert Crawl Space Encapsulation Services
As a leading basement, crawl space, and foundation waterproofing company, Sedona Waterproofing Solutions provides expert crawl space encapsulation services.

Concord, North Carolina – May 13, 2024 – Sedona Waterproofing Solutions, the leading basement, crawl space, and foundation waterproofing company, provides expert crawl space encapsulation and mold remediation in Charlotte NC. Their team of experienced professionals is dedicated to providing customized solutions tailored to your specific needs and budget.

Mold-Remediation-in-Charlotte-NC

When asked about their crawl space encapsulation in Charlotte NC, their spokesperson said, “At Sedona Waterproofing Solutions, we understand the unique challenges that homeowners face when it comes to moisture control. With years of experience in the industry, our technicians have the knowledge and skills to deliver superior results. We utilize the latest techniques and technology to ensure that your crawl space waterproofing in Charlotte NC is properly encapsulated for maximum protection.”

They use only the highest quality materials for all their projects including Charlotte NC waterproofing. Their crawl space encapsulation products are durable, long-lasting, and designed to withstand the rigors of Charlotte’s climate.

“We take pride in our meticulous attention to detail. From thorough inspections to precise installation, we go above and beyond to ensure that every aspect of your crawl space encapsulation is completed to the highest standards. Your satisfaction is our top priority. We strive to exceed your expectations at every turn, providing responsive communication, transparent pricing, and unparalleled customer service”, added the spokesperson.

Crawl space encapsulation is a smart investment that can enhance the value and marketability of your home, making it more attractive to potential buyers. With their expertise and commitment to excellence, you can trust them to protect your home for years to come.

About Company

Sedona Waterproofing Solutions, the leading basement, crawl space, and foundation waterproofing company, provides expert crawl space encapsulation and mold remediation. They strive to exceed your expectations at every turn, providing responsive communication, transparent pricing, and unparalleled customer service. Visit https://www.sedonawaterproofing.com/.

Media Contact
Company Name: Sedona Waterproofing Solutions
Contact Person: Josh Landrio
Email: Send Email
Phone: +1 704-960-7906
Address:188 Crowell Dr NW
City: Concord
State: Cabarrus
Country: United States
Website: https://www.sedonawaterproofing.com/

GSK Building Solutions Recognised as A Trustworthy Partner in Post Construction Cleaning

GSK Building Solutions Recognised as A Trustworthy Partner in Post Construction Cleaning
GSK Building Solutions offers comprehensive post-construction cleaning services in Sydney, including builders cleaning, construction cleaning, and after construction cleaning.

Sydney – May 13, 2024 – GSK Building Solutions, a leading provider of construction cleaning services in Sydney, is proud to announce their commitment to delivering top-notch post-construction cleaning solutions for residential, commercial, and industrial projects. With a wide range of services tailored to meet the needs of any industry, GSK Building Solutions is committed to delivering excellent results for their clients.

Builders-cleaning-Sydney

Builders cleaning Sydney, construction cleaning Sydney, after construction cleaning Sydney, and post construction cleaning Sydney are all critical aspects of the construction process. Whether it’s removing debris, cleaning windows, or performing site clean-up, GSK Building Solutions is dedicated to ensuring that newly built or renovated properties are spotless and ready for occupancy.

With a team of highly trained professionals and state-of-the-art equipment, GSK Building Solutions offers a comprehensive range of services to meet the diverse needs of their clients. From builders final cleans to commercial demolition specialist services, GSK Building Solutions has the expertise and experience to handle any project, regardless of size or complexity.

“Our mission at GSK Building Solutions is to provide exceptional post-construction cleaning services that exceed our clients’ expectations,” said the spokesperson of GSK Building Solutions.

“We understand the importance of a clean and safe environment, and we are committed to delivering superior results for every project we undertake.”

In addition to builders cleaning and construction cleaning, GSK Building Solutions also offers a variety of other services, including window cleaning, strata cleaning, commercial cleaning, and graffiti removal. With their comprehensive range of services, GSK Building Solutions is equipped to handle all aspects of post-construction cleaning, ensuring that properties are pristine and ready for use.

About GSK Building Solutions:

GSK Building Solutions is a leading provider of post-construction cleaning services in Sydney, offering builders cleaning, construction cleaning, and after construction cleaning solutions for residential, commercial, and industrial projects. With a commitment to excellence and customer satisfaction, GSK Building Solutions strives to deliver superior results for every client. For more information, visit https://gskbuildingsolutions.com.au/.

Media Contact
Company Name: GSK Building Solutions
Contact Person: George Kalousian
Email: Send Email
Phone: +61 43 412 6004
Country: Australia
Website: https://gskbuildingsolutions.com.au/

Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight’s, “Triple Negative Breast Cancer Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Triple Negative Breast Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Triple Negative Breast Cancer Pipeline Report

  • DelveInsight’s Triple Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline treatment therapies.
  • The leading Triple Negative Breast Cancer Companies working in the market include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.
  • May 2024:- Gilead Sciences- A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy. The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician’s choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
  • May 2024:- Wake Forecast University Health Sciences- ToPCourT: A Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC). The goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer.
  • May 2024:- Kathy Miller- A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers. This is a randomized Phase II study of carboplatin monotherapy vs. carboplatin combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.

 

Request a sample and discover the recent advances in Triple Negative Breast Cancer @ Triple Negative Breast Cancer Pipeline Outlook Report

 

Triple Negative Breast Cancer Overview

Triple Negative Breast Cancer (TNBC) is defined as a tumor where the estrogen and progesterone (ER/PR) are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. TNBCs are frequently identified as hyper dense masses without associated calcifications.

 

Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted HER2 drugs work. Because hormone therapy and anti-HER2 drugs are not choices for women with triple-negative breast cancer, chemotherapy is often used. If the cancer has not spread to distant sites, surgery is an option.

 

Triple Negative Breast Cancer Emerging Drugs

 

  • Camrelizumab: Jiangsu HengRui Medicine

Camrelizumab (Airuika) is a humanized monoclonal antibody acts as immunomodulatory agent. It is formulated as solution for intravenous route. Camrelizumab is indicated as third-line treatment for recurrent or refractory classical hodgkin’s lymphoma, advanced hepatocellular carcinoma patients with oxaliplatin system chemotherapy, combined with pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation negative and anaplastic lymphoma kinase (ALK) negative, non-resectable locally advanced or metastatic first-line treatment of non-squamous non-small cell lung cancer (NSCLC), locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and whose disease has progressed or become intolerable and for the treatment of patients with advanced nasopharyngeal carcinoma who had disease progression after previous second-line and above chemotherapy or intolerable treatment. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of Triple Negative Breast Cancer.

 

  • IPI-549: Infinity Pharmaceuticals

IPI-549 is under development for the treatment of solid tumors including metastatic renal cell cancer, soft tissue sarcoma and prostate cancer, triple negative breast cancer, colon cancer, metastatic melanoma, non-small cell lung cancer, glioblastoma multiforme, microsatellite-stable gallbladder carcinoma, head and neck cancer squamous cell carcinoma, mesothelioma, ovarian cancer, adrenocortical carcinoma and metastatic urothelial cancer including renal pelvis cancer, ureter cancer, bladder cancer, urethra cancer.

 

  • PMD-026: Phoenix Molecular Designs

PhoenixMD’s lead candidate, PMD-026, is the first RSK inhibitor being developed for the treatment of TNBC. It is a pill that is convenient for patients as opposed to intravenous delivery, the mode most commonly used to deliver chemotherapy. PMD-026 was designed for TNBC because RSK2 was specifically identified as the key kinase that drives the growth of this breast cancer subtype5, 6. PMD-026 is well-tolerated in breast cancer patients and can stop tumor growth for up to 5 months based on Phase 1 data.

 

Learn more about Triple Negative Breast Cancer in clinical trials @ Triple Negative Breast Cancer Drugs

 

Triple Negative Breast Cancer Therapeutics Assessment

There are approx. 75+ key companies which are developing the therapies for Triple Negative Breast Cancer. The Triple Negative Breast Cancer companies which have their Triple Negative Breast Cancer drug candidates in the most advanced stage, i.e. phase III include, Jiangsu HengRui Medicine.

 

DelveInsight’s Triple Negative Breast Cancer Pipeline report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Discover more about Triple Negative Breast Cancer in development @ Triple Negative Breast Cancer Clinical Trials

 

Triple Negative Breast Cancer Companies

Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.

 

Triple Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.

 

Triple Negative Breast Cancer Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

To know more about Triple Negative Breast Cancer, visit @ Triple Negative Breast Cancer Segmentation

 

Scope of the Triple Negative Breast Cancer Pipeline Report

  • Coverage- Global
  • Triple Negative Breast Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Triple Negative Breast Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Triple Negative Breast Cancer Companies- Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, and others.
  • Triple Negative Breast Cancer Therapies- Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Taxotere® (100 mg/m2), B013+Nab-Paclitaxel, ZEN003694, Talazoparib, Pembrolizumab, Sacituzumab Govitecan-hziy, Datopotamab Deruxtecan (Dato-DXd), and others.

 

For further information on the Triple Negative Breast Cancer Pipeline Therapeutics, reach out @ Triple Negative Breast Cancer Products Development

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Triple Negative Breast Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Triple Negative Breast Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Camrelizumab: Jiangsu HengRui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. IPI-549: Infinity Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PMD-026: Phoenix Molecular Designs
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Triple Negative Breast Cancer Key Companies
  18. Triple Negative Breast Cancer Key Products
  19. Triple Negative Breast Cancer- Unmet Needs
  20. Triple Negative Breast Cancer- Market Drivers and Barriers
  21. Triple Negative Breast Cancer- Future Perspectives and Conclusion
  22. Triple Negative Breast Cancer Analyst Views
  23. Triple Negative Breast Cancer Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Triple Negative Breast Cancer Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

Global Iconic Changemakers of The 21st Century: A Collaborative Endeavor by T & R Birthing Books Publishing

Global Iconic Changemakers of The 21st Century” celebrates visionary leaders worldwide. Join the live launch event on May 19th!

T & R Birthing Books Publishing is proud to announce the upcoming release of “Global Iconic Changemakers of The 21st Century,” a global book collaboration featuring visionary leaders from around the world. Scheduled for release on Sunday, May 19th, 2024, this transformative project celebrates the extraordinary individuals who are driving positive change in our society.

The launch event, set to take place at 6pm CST, will introduce audiences to the remarkable coauthors who have contributed their insights and experiences to this inspirational volume. From humanitarians to leaders and changemakers, these individuals represent diverse backgrounds and cultures united by a shared commitment to making a lasting impact on our world.

“We are thrilled to unveil this collaborative effort that showcases the collective wisdom and vision of our esteemed coauthors,” said Dr. Rosalind Willis, founder of T & R Birthing Books Publishing. “Through their stories and journeys, readers will be inspired to embrace their own potential for positive change and contribute to a better future for all.”

Video Link: https://www.youtube.com/embed/RXkPTR_FiDI?si=vcs1kgdYg8bZ3qs5

The live stream event, which will be broadcast on YouTube, promises to be a momentous occasion filled with celebration and inspiration. Audiences can expect to hear firsthand from the coauthors as they share their personal stories, insights, and the driving forces behind their transformative work.

“We invite everyone to join us for this historic event as we celebrate the power of collaboration and the spirit of positive change,” added Dr. Willis. “Together, let’s mark this milestone in literary history and honor the incredible contributions of these global iconic changemakers.”

Among the esteemed coauthors featured in the book are Dr. Raymond Banzuela, Amb. Helen Hirang-Amante, Dr. Randi Ward, Dr. Shawn Saxton, Amb. Dr. Sara Sanchez, Dr. Veleria Chambers, Dr. Chebra Dorsey, Dr. Dorothy Wolons, Dr. Robbie Motter, Dr. Lakisha James, Dr. Mireille Toulekima, Dr. Desziree Richardson, Dr. Amber Lyons, Coach Tonni Lea-Larson, Amb. Caroly Liege, Dr. Dominique Carson, Sister Shana Gourdine, Lady Dr. Amb. Lenora Wimberly-Perterson, Dr. Caroline Makaka, Dr. Shamika Livingston, and Elder Tommy & Dr. Rosalind Willis.

The eBook version of “Global Iconic Changemakers of The 21st Century” will be available on Amazon starting May 19th, 2024, with the paperback edition to follow on May 31, 2024. For aspiring authors interested in publishing their own transformative works, T & R Birthing Books Publishing offers expert guidance and support.

For media inquiries or to learn more about the publication process, please visit their website.

Media Contact
Company Name: T & R Birthing Books Publishing
Contact Person: Dr. Rosalind Willis
Email: Send Email
Phone: +1 ‪(806) 416-7159‬
Country: United States
Website: www.trbirthingbookspublishing.site

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global Iconic Changemakers of The 21st Century: A Collaborative Endeavor by T & R Birthing Books Publishing

TCR Therapy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

DelveInsight’s, “TCR Therapy Pipeline Insight 2024” report provides comprehensive insights about 30+ companies and 100+ pipeline drugs in TCR Therapy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the TCR Therapy Pipeline Report

  • DelveInsight’s TCR Therapy pipeline report depicts a robust space with 30+ active players working to develop 100+ pipeline therapies for TCR Therapy treatment.
  • The leading TCR Therapy Companies working in the market include Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.
  • Promising TCR Therapy Therapies in the various stages of development include TCR-T cells, Interleukin-2, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, and others.
  • May 2024:- TScan Therapeutics Inc.- A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors. TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules.
  • April 2024:- TCRCure Biopharma Ltd- A Phase I/II Clinical Trail of TC-E202 Targeting HPV16 E6 for Relapsed/Refractory to Standard Treatment or Metastatic Cervical Carcinoma. Cervical cancer is the most common gynecologic malignant tumor. The occurrence and progression of cervical carcinoma is firmly relevant to HPV (Human papilloma virus) infection. Cancer cells infected by HPV expressing an HPV protein called E6. E6 is the main factors of HPV 16 carcinogenesis.

 

Request a sample and discover the recent advances in TCR Therapy @ TCR Therapy Pipeline Outlook Report

 

TCR Therapy Overview

The T-cell receptor (TCR) is a molecule found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate, that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

 

The signal transduction mechanism by which a T cell elicits this response upon contact with its unique antigen is termed T-cell activation (just as phototransduction is the term given to the signal transduction event by which photoreceptors elicits vision upon exposure to photons). There are myriad molecules involved in the complex biochemical process (called trans-membrane signaling) by which T-cell activation occurs. The most common mechanism for activation and regulation of molecules beneath the lipid bilayer is via reversible tyrosine phosphorylation by protein kinase/phosphatase.

 

TCR Therapy Emerging Drugs

 

  • IMC F106C: Immunocore

IMC-F106C is an ImmTAC targeting PRAME for patients with HLA-A02, which is expressed in approximately 40% of Western populations (United States, Canada, EU). In order to expand the potential of TCR therapy targeting PRAME, the Company is developing IMC-T119C, a first-in-class ImmTAC product candidate targeting a PRAME peptide presented by HLA-A24. HLA-24 is an HLA-type that is estimated to be present in 60% of people in Japan and 15-20% in Western populations. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of patients with 1L advanced, cutaneous melanoma.

 

  • GSK 3377794: GlaxoSmithKline

GSK 3377794 developed by GlaxoSmithKline is an investigational SPEAR T-cell receptor targeting NY-ESO-1. GSK ‘794 is an engineered T-cell therapy, for which a patient’s own cells have been genetically modified to express a T-cell receptor (TCR) recognizing with high affinity the tumor-specific antigen, NY-ESO. When the modified cells are re-infused into the patient, they recognize and kill tumor cells that express the NY-ESO antigen.

 

  • MDG 1011: MediGene AG

MDG1011 is a TCR-T immunotherapy directed against the tumor antigen PRAME (Preferentially expressed Antigen in Melanoma) and was manufactured to be administered in a single intravenous dose to patients suffering from relapsed or refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or multiple myeloma (MM) who had previously undergone extensive pre-treatment with standard or experimental therapies. Currently the drug is in Phase I/II stage of clinical trial evaluation for the treatment of patients with High Risk Myeloid and Lymphoid Neoplasms.

 

  • TSC-100: TScan Therapeutics

TSC-100 is HA-1 and HA-2 specific TCR-T candidates directed at eliminating native blood cells, including residual cancer cells, in target-positive and HLA-A*02:01-positive patients undergoing hematopoietic cell transplantation (HCT). TSC-100 was identified using ReceptorScan from hundreds of millions of CD8+T cells. The therapies is designed to elicit an anti-tumor response in patients by targeting HA-1 or HA-2 minor antigens, which are present on malignant and normal blood cells of patients but not on any of the new, donor-derived blood cells.

 

Learn more about TCR Therapy in clinical trials @ TCR Therapy Drugs

 

TCR Therapy Therapeutics Assessment

There are approx. 30+ key TCR Therapy companies which are developing the therapies for TCR Therapy. The TCR Therapy companies which have their TCR Therapy drug candidates in the most advanced stage, i.e. Phase III include, Immunocore.

 

DelveInsight’s TCR Therapy pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Discover more about TCR Therapy in development @ TCR Therapy Clinical Trials

 

TCR Therapy Companies

Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.

 

TCR Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

TCR Therapy Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

To know more about TCR Therapy, visit @ TCR Therapy Segmentation

 

Scope of the TCR Therapy Pipeline Report

  • Coverage- Global
  • TCR Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • TCR Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • TCR Therapy Companies- Immunocore, GlaxoSmithKline, Altor BioScience Corporation, Immatics, SCG Cell Therapy, Baudax Bio, TScan Therapeutics, 2seventy bio, Treadwell Therapeutics, T-Knife, Triumvira, Abata Therapeutics, Affini-T Therapeutics, Lion TCR, Poseida Therapeutics, Athenex, Inc., Adaptimmune, Neogene Therapeutics, Alaunos Therapeutics, MediGene AG, Zelluna Immunotherapy, and others.
  • TCR Therapy Therapies- TCR-T cells, Interleukin-2, VX-121/TEZ/D-IVA, ELX/TEZ/IVA, and others.

 

For further information on the TCR Therapy Pipeline Therapeutics, reach out @ TCR Therapy Products Development

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. TCR-Therapy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. TCR-Therapy – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. IMC F106C: Immunocore
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GSK 3377794: GlaxoSmithKline
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. TSC-100: TScan Therapeutics
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. TCR-Therapy Key Companies
  18. TCR-Therapy Key Products
  19. TCR-Therapy- Unmet Needs
  20. TCR-Therapy- Market Drivers and Barriers
  21. TCR-Therapy- Future Perspectives and Conclusion
  22. TCR-Therapy Analyst Views
  23. TCR-Therapy Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: TCR Therapy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)

Completed Merger Leads to Very High-Value Business in International Military and Defense Products with LOI Already Signed on $370 Million Order for Saudia Arabia: NAPC Defense, Inc. (OTC: BLIS)

Definitive Agreement for Merger and Acquisition with Native American Pride Constructors, LLC (“NAPC”) of Largo, FL.

Military Products Sales & Production Company, Fully Licensed in the United States with Exclusive Rights to Produce and Sell Corner Shot USA Systems. 

LOI for Initial 37,000-unit Order, Equivalent to $370 Million in Revenue, From a Leading Saudi Arabian Supply Chain and Manufacturing Provider. 

Field Demonstrations Will Occur in Saudi Arabia During a Visit Set for the First Two Weeks of July 2024.

Active in Brokering of Military Hardware Already Produced and in Inventory at Various Locations Worldwide.

Inventory of All Items Totals Over $2.5 Billion USD.

NAPC Defense, Inc. (OTC: BLIS) is a military products sales and production company, fully licensed in the United States, with exclusive rights to produce and sell Corner Shot USA Systems, in addition to brokering other defense products throughout the world all with US State Department approval. Additional smaller military platforms and related products are in development.  

Company Name Change to NAPC Defense, Inc. and Website to NAPCDefense.com among Business Updates

Also Set Visit to Saudi Arabia for Presentation of Military and Defense Systems

On May 13h BLIS, NAPC Defense, Inc. (formerly known as Treasure & Shipwreck Recovery, Inc.), announced that it had completed the change of name with the State of Nevada and registration with the State of Florida, as well as a new website at www.NAPCDefense.com. BLIS is also finalizing its application with FINRA to effect all additional merger terms announced in its March 27, 2024 press release. BLIS owns defense and construction contracting firm Native American Price Constructors, LLC.

More importantly, BLIS updated its intended large purchase order from a Saudi Arabian company. Field demonstrations for the BLIS The Corner Shot Systems will occur in the Kingdom of Saudi Arabia before government, military, and other officials during a visit set for the first two weeks of July 2024.

While BLIS maintains a government contracting business, its business includes The Corner Shot Systems, which is licensed for the United States and the Middle East, as well as brokering of military product sales through allied countries, as approved by the U.S. State Department.

The Saudi Arabia meetings will be for assessment and introduction of the continued contract goal of providing the BLIS Corner Shot technology to Saudi Arabia, under a U.S.-approved and licensed export of the tactical technology. BLIS is a joint venture partner in Saudi Arabia, in the joint venture of NAPC-KSA which is co-owned by BLIS, Kingswood Holding LLC., and AL-SAQR AL–HARR Limited Company. BLIS already has a signed and stamped LOI from a leading Saudi Arabian provider of supply and manufacturing to the Ministry of Defense (MOD).

BLIS management is also in discussion with the Kingdom of Saudi Arabia to provide additional services in the country, pending expected U.S. State Department approval. BLIS management expects significant discussions to expand during the official visit to this arena.

In expanding its military products business, BLIS is also developing specialized items for domestic government and international sales. BLIS expects to release more information on these product lines in the short term as prototypes are being completed for testing.

BLIS will also be participating in a number of law enforcement conventions to display The Corner Shot and other product lines. Such conventions and shows include Florida Police Chiefs Assoc. 72nd Annual Summer Training Conference & Exposition in Pointe Vedra Beach, FL – June 7th – 12th 2024 (Booth #139) and 38th Annual NJ Police Security Expo. in Atlantic City, NJ – June 24th – 26th (Booth #1037).

BLIS is now active in brokering of military hardware already produced and in inventory at various locations worldwide. BLIS is currently brokering a number of military items that are of interest to Allied and NATO forces for Ukraine and the Middle East, which also require U.S. State Department approval. Any successful transaction would add significantly to BLIS revenues and profits. The inventory of these items, if sold at currently offered fair value, totals over (U.S.) $2.5 billion.

Definitive Agreement for Merger and Acquisition with Defense and Construction Contracting Firm Native American Pride Constructors, LLC. (NAPC)

LOI for Initial 37,000-unit Order, Equivalent to $370 Million in Revenue, From a Leading Saudi Arabian Supply Chain and Manufacturing Provider

On March 27th BLIS announced it successfully concluded its due diligence and signed a Definitive Agreement for merger and acquisition with Native American Pride Constructors, LLC (“NAPC”) of Largo, FL.

NAPC, established in 2015, is a stable, profitable entity focused primarily on government contracts with existing licenses that allow it to bid and win contracts in the Defense, Munitions, and Construction industries. With this merger, BLIS is projected to deliver over $5,000,000 in backlog revenue for the calendar year 2024, which does not include sales of Corner Shot Systems or brokering of defense items for use by Allied and NATO forces in the Ukraine and the Middle East.

The projections for Corner Shot USA are impressive and strong interest from domestic agencies was generated from its presence at the 2024 Shot Shell Show, held this past January in Las Vegas. NAPC plans to have space at four more shows in 2024 primarily focused on domestic police departments and SWAT teams.

Additionally, BLIS also received a signed and stamped LOI from a leading Saudi Arabian provider of supply and manufacturing to the Ministry of Defense (MOD) as well as the procurement division GAMI (General Authority Military Industries – Government Entity).

The LOI discusses the initial intent to purchase 37,000 units; a 4,000-unit tranche followed by subsequent deliveries of 3,000 units per month until that quantity is fulfilled. The cost of this order would produce $370,000,000 in sales with a net profit margin of at least 20% to BLIS. The LOI provides intent to purchase an additional 63,000 units after delivery of the first 37,000 units, over a period of the next ten years. 

BLIS believes it will finalize firm purchase orders and collect a 50% deposit on the first order by the end of June and go into production in July of 2024. In addition, BLIS management is in discussion with the Kingdom of Saudi Arabia to provide additional product services in the country, pending expected U.S. State Department approval.

Another BLIS area of expertise is brokering of military hardware already produced and in inventory at various locations worldwide, BLIS is brokering more than eleven different military hardware items that are of interest to Allied and NATO forces in the Ukraine and the Middle East, which also require U.S. State Department approval. 

For more information on $BLIS visit: www.NAPCDefense.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: NAPC Defense, Inc.
Contact Person: Kenny West, CEO
Email: Send Email
Phone: 754-242-6272
Address:1501 Lake Avenue, SE Largo, Fla. 33771
City: Largo
State: Florida
Country: United States
Website: www.NAPCDefense.com

New Company Officers Appointed After Promising Preclinical Data on Gene Therapy for Anti-Tumor Mechanisms with Ability to Trigger Cancer Cell Death: Genprex, Inc. (NASDAQ: GNPX)

Gene Therapy Focused on Life-Changing Developments for Cancer and Diabetes. 

Working With World-Class Institutions and Collaborators to Provide Novel Treatment Approaches.

 New Top Company Officers Appointed with High Qualifications and Experience. 

High Profile Presentations at May 2024 Investor and Industry Conferences. 

Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments.

Studies Presented at the April 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California.

REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Cancer Cell Death.

Genprex, Inc. (Nasdaq: GNPX) is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. GNPX technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. GNPX works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The GNPX oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. 

The GNPX lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of the GNPX three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and the GNPX SCLC program has received an FDA Orphan Drug Designation. 

The GNPX diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

On May 13th GNPX announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the passing of the Company’s co-founder and previous Chairman Rodney Varner.

Prior to his appointment as Chairman, Mr. Moreno Toscano has served on the GNPX Board of Directors since March 2020. Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc, the US subsidiary of LFB Group, a global integrated biopharmaceutical company, and he has more than 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations, and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations, and general management.

Mr. Moreno Toscano’s appointment follows the recent appointment of Ryan Confer to serve as GNPX President and Chief Executive Officer. Mr. Confer was also appointed to Genprex’s Board of Directors.

Presentations at May 2024 Investor and Industry Conferences

For the month of May, GNPX announced participation in the following investor and industry conferences: 

Event: Sidoti Microcap ConferenceConference Dates: May 8-9, 2024Presentation Date: Wednesday, May 8, 2024Presentation Time: 3:15 p.m. ETVenue: VirtualGNPX Presenter: Ryan Confer, Genprex’s Chief Financial OfficerPresentation link: https://bit.ly/3UlTsgl

An archive of the presentation will be available in the Investor Relations section of the GNPX website. 

Event: American Society of Gene & Cell Therapy Annual MeetingDates: May 7-11, 2024Location: Baltimore Convention CenterGNPX Participant: Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing. 

Positive Preclinical Data on GNPX Reqorsa® and NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers

On April 9th GNPX announced that its research collaborators presented positive preclinical data for Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid) and NPRL2 gene therapy, which both utilize the Company’s non-viral Oncoprex® Delivery System for the treatment of lung cancer. These studies were presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, 2024 in San Diego, California.

In the first GNPX poster, entitled “Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing Non-Small Cell Lung Carcinoma can induce cellular apoptosis,” researchers reported that REQORSA induced apoptosis in alectinib resistant EML4-ALK positive non-small cell lung cancer (NSCLC) cell lines. Alectinib is an ALK-inhibitor commonly used to treat patients with ALK rearrangements such as EML4-ALK positive NSCLCs. This research suggests that REQORSA may be an effective treatment in patients progressing on alectinib.

The second GNPX poster, entitled, “Mechanism of NPRL2 gene therapy-induced anti-tumor immunity in KRAS/STK11mt aPD1 resistant metastatic NSCLC” detailed a humanized mouse model study in which the researchers investigated the anti-tumor immune responses to NPRL2 gene therapy in pembrolizumab resistant KRAS/STK11mt NSCLC. In the study, lung metastases in humanized mice were treated through I.V. injection of NPRL2 nanoparticles, made with the ONCOPREX Delivery System, with or without pembrolizumab. The study found that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect. Additionally, a greater anti-tumor effect was seen in humanized compared to non-humanized mice, demonstrating that immune cells play a role in the effects of the NPRL2 nanoparticle therapy. Study findings suggest that NPRL2 gene therapy induces anti-tumor activity against KRAS/STK11mt tumors through dendritic cell-mediated antigen presentation and cytotoxic immune cell activation. The Company believes this data could support the potential for a new drug candidate in its pipeline, and it also provides further evidence for the Company’s belief that the ONCOPREX Delivery System can be successful using genes other than the TUSC2 gene the Company is already using in clinical trials with REQORSA.

In the GNPX third poster, entitled, “Tumor Suppressor Gene TUSC2 suppresses energy metabolism in lung cancer cells with opposite effects in normal bronchial epithelial cells” researchers reported that TUSC2-deficient cancer cells consistently exhibited decreased glycolytic rates and mitochondrial ATP production, leaving these cells without enough energy to support their vital functions. By comparison, when Beas2B, a normal human bronchial epithelial cell line with normal levels of TUSC2, was transfected with a TUSC2-containing plasmid, the glycolytic rate and mitochondrial metabolism were increased. This suggests the mechanism by which REQORSA treatment affects immune and other non-cancerous cells that leads to increased immune response against tumors. The study further suggested that REQORSA may play an important role as a cancer treatment to target and disrupt the metabolism of cancer cells, leading to a decrease in the rate of glycolysis.

These AACR posters have been made available on the GNPX website at www.genprex.com.

For more information on $GNPX visit: www.genprex.com  and https://compasslivemedia.com/gnpx/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Genprex, Inc.
Contact Person: Ryan M. Confer, MS, President, CEO, CFO
Email: Send Email
Phone: 8777744679
Address:3300 Bee Cave Road Suite 650-227
City: Austin
State: Texas
Country: United States

Stevia Select Sheds Light on the Sweetener Enigma: Erythritol vs. Stevia

Unveiling the healthier sweetener choice.

Stevia Select, the home of ‘Healthy Meets Tasty,’ continues its commitment to wellness and natural products by promoting the broader use of its pure stevia – erythritol free and containing no fillers. With a growing preference for sugar substitutes, the leading provider of pure stevia products is shedding light on the sweetener enigma, particularly when it comes to stevia and erythritol.

Since erythritol is generally considered safe as an artificial sweetener, the sugar alcohol is present in most ‘natural’ stevia products. But is it the same as pure stevia? Diana Hovland, the founder of Stevia Select, echoes a resounding no, citing the potential downsides of erythritol and emphasizing the importance of stevia without additives.

Erythritol, a sugar alcohol derived from corn starch and often genetically modified (GMO), has been the focus of several studies. While it boasts zero calories, concerns about its potential health risks have been raised in various studies. Erythritol has been linked to an increased risk of cardiovascular issues, including heart attack and stroke, and it may also influence hormonal problems. Furthermore, animal studies have linked the consumption of GMOs to issues like faulty insulin regulation, accelerated aging, infertility, immune problems, and changes in major organs and the gastrointestinal system, prompting ongoing studies.

On the other hand, stevia is a naturally occurring plant extract that offers people a guilt-free way to indulge their sweet tooth. According to Diana, organic stevia, unlike erythritol, provides a natural, gut-friendly sweetener. Stevia boasts more than just a clean taste; the sweetener is gentle on the stomach, making it ideal for individuals who suffer from IBS, autoimmune diseases, and leaky gut. Pure stevia is also the best option for people who experience adverse side effects like nausea, gas, bloating, and cramps from consuming sugar alcohols.

For people seeking sweetness without compromising their health, Stevia Select offers a healthier and more natural approach to sweetness with its pure stevia products. Stevia Select provides a range of premium organic stevia products free from fillers and potentially risky erythritol. The products are available in 14 unique flavors, liquid stevia drops, and the popular pure organic stevia powder.

Discover a world of healthy sweetness with Stevia Select’s great-tasting 100% pure organic stevia.

Media Contact
Company Name: Stevia Select
Contact Person: Diana Hovland
Email: Send Email
Country: United States
Website: https://steviaselect.com/

AAA Tree Experts Is the Premier Arborists for Tree Removal and Stump Grinding

AAA Tree Experts Is the Premier Arborists for Tree Removal and Stump Grinding
AAA Tree Experts, Charlotte’s leading arborists, offer expert tree removal and stump grinding services. With over 25 years of experience, we prioritize safety, efficiency, and preserving the beauty of the landscape.

Charlotte, North Carolina – May 13, 2024 – AAA Tree Experts, the trusted name in tree care services, continues to serve the Charlotte area with unparalleled expertise and dedication. With a legacy spanning over two decades, AAA Tree Experts remains committed to providing top-notch Charlotte arborist services, including tree removal, stump grinding, and tree care, enhancing the beauty and safety of properties throughout the region.

Charlotte-Arborist

Recognizing the importance of maintaining the health and aesthetics of the landscape, AAA Tree Experts offers comprehensive tree care solutions tailored to meet the unique needs of each client.

When asked about their service, the spokesperson of AAA Tree Experts replied, “As certified arborists, we prioritise the preservation of trees whenever possible, but also understand the necessity of tree removal in certain circumstances. Our team utilises the latest arborist techniques and equipment to ensure safe and efficient tree removal Charlotte, addressing concerns such as precariously positioned trees and those in close proximity to utility wires.”

In addition to tree removal, AAA Tree Experts specialises in stump grinding, offering a less abrasive and cost-effective method for tree stump removal Charlotte. With a depth of expertise in stump grinding Charlotte, their team ensures minimal disruption to the landscape while effectively eliminating unsightly stumps and creating space for new growth.

“Our mission at AAA Tree Experts is to preserve and enhance the beauty of Charlotte’s landscape while prioritizing safety and sustainability,” says spokesperson of AAA Tree Experts.

“We take pride in our commitment to excellence and strive to exceed our clients’ expectations with every project.”

About AAA Tree Experts:

Founded in 1996 by Wayne Neal, AAA Tree Experts is a leading provider of arborist services in Charlotte, NC. With over 25 years of experience, their team of certified arborists specialises in tree removal, stump grinding, tree care, and landscaping services. Committed to preserving the beauty and health of Charlotte’s trees, they offer expert residential and commercial services throughout the Charlotte area and surrounding regions. To learn more, visit https://aaatrees.net.

Media Contact
Company Name: AAA Tree Experts
Contact Person: Kristen Neal
Email: Send Email
Phone: +1 704-366-1134
Address:9535 Hebron Commerce Dr
City: Charlotte
State: North Carolina
Country: United States
Website: https://aaatrees.net

Billi’s Cafe is the Ideal Destination for Memorable Gatherings & Gourmet Experiences

Billi’s Cafe is the Ideal Destination for Memorable Gatherings & Gourmet Experiences
The renowned cafe offers convenient event venues and delicious dishes for guests to dine and unwind.

McMahons Point, NSW – May 13, 2024 – Nestled in the heart of McMahons Point, Billi’s Cafe offers more than just a dining experience. It is a vibrant community hub where good food, great reads, and unforgettable moments come together. With its inviting ambience and tasty cuisines, Billi’s Cafe has become one of the sought-after Milsons Point cafes for family gatherings and special events.

Milsons-Point-cafes

“From intimate get-togethers to larger celebrations, Billi’s Cafe is the ideal spot for any event. Whether you are celebrating a birthday or a corporate milestone, our heartwarming atmosphere and good food can make your event truly special. We offer a range of nutritious and quality dishes that will add an exceptional dining experience for all our guests,” a spokesperson for the company said.

Guests can choose between a scenic outdoor terrace, a cosy private room lined with books, and a spacious dining area based on their requirements. Their venue also has sufficient seating and standing room to accommodate any number of guests.

As one of the renowned restaurants McMahons Point, Billi’s Cafe has been offering an exquisite range of drinks and dishes for breakfast, lunch, and dinner. They have been popular amongst the locals for over 15 years, thanks to their quality ingredients and traditional recipes.

“People are drawn to the welcoming atmosphere and Billi’s passion for and commitment to making authentic home-grown meals and beverages. Between our homemade granola, bircher, banana bread, pastries, chai and even almond milk, you’ll soon feel like you’re back in grandma’s kitchen,” said the spokesperson.

From the revitalising allure of coffee to the crispy delight of Chicken Parmigiana, everything is prepared by using only fresh quality ingredients. Their team of talented chefs are fully qualified in preparing these nutritious and flavoursome dishes. Billi’s Cafe is one of the few restaurants on Blues Point Road catering to guests who require exceptional quality, homegrown food.

For guests who love book reading, Billi’s Cafe has a bookstore that houses over 30,000 books across 3 floors. Pick a book from the shelf and read on while enjoying a cup of freshly brewed coffee. Customers are also allowed to purchase the book if necessary.

The Lavender Bay restaurant offers customisable function packages to suit the varying needs of their guests. Interested clients can visit their official site and fill out a form online to describe the requirements.

About Company:

Billi’s Cafe is a popular cafe that offers exceptional dining and vibrant event venues. To know more, visit https://www.billiscafe.com.au/

Media Contact
Company Name: Billis Cafe
Contact Person: Vangel Cvetkovski
Email: Send Email
Phone: +61 2 890 40111
Address:133-135 Blus Point Rd
City: McMahons Point
State: NSW
Country: Australia
Website: https://www.billiscafe.com.au/